NCT04334837Approved For Marketing不适用
An Open-Label, Multi-Center Expanded Access Protocol of Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of Somatostatin Receptor Expressing Neuroendocrine Tumors (NETs)
适应症
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This is an open-label, multi-center expanded access program designed to provide access to Copper Cu 64 Dotatate for the detection, localization, and monitoring of NETs to patients that did not have access during the Phase 3 Trial.
详细描述
The objective of this trial is to provide patients with confirmed or suspicion of NET access to Copper Cu 64 Dotatate for the detection, localization, and monitoring of SSTR expressing NETs, bridging the gap between investigational product availability in clinical studies and marketed product availability following US Food and Drug Administration (FDA) approval.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of either sex, aged ≥18 years.
- •Willing to sign the Informed Consent Form.
- •Able to understand and comply with the procedures and requirements of the program.
- •Meet at least one of the following criteria:
- •Confirmed or suspicion of NET based on histology/biopsy report.
- •Confirmed or suspicion of NET based on conventional imaging scans of affected area such as MRI and/or contrast enhanced CT and/or an FDG PET-CT scan and/or NaF PET-CT scan and/or OctreoScan® and/or clinical symptoms performed within 8 weeks prior to administration of Copper Cu 64 Dotatate.
- •Negative pregnancy test in women of child-bearing potential, using urine (dip stick test) or blood based testing (within 48 hours of injection).
- •For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods for at least 2 weeks following administration of investigational product.
- •For men, agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures for at least 2 weeks following administration of investigational product.
- •Recent blood test results (within 4 weeks pre-dose) as follows:
- •WBC: >2 x 109/L
- •Hemoglobin: >8.0g/dL
- •Platelets: >50 x 109/L
- •ALT, AST, AP: ≤5 times ULN
- •Bilirubin: ≤3 times ULN
- •Serum creatinine: <170 μmol/L
排除标准
- •Pregnant, planning to be pregnant within the next two weeks.
- •Therapeutic use of any somatostatin analogue, including Sandostatin® LAR and Lanreotide (within 28 days) and Sandostatin® (within 2 days) prior to administration with Copper Cu 64 Dotatate. If a patient is on Sandostatin® LAR or Lanreotide, a wash-out period of 28 days is required before the injection of the investigational product.
- •History or presence of significant hematological abnormalities or immunodeficiency or any condition that might compromise the immune system (infections, vaccinations), of any etiology as indicated by clinically significantly abnormal values of any of the following hematologic parameters: platelets, hemoglobin, WBC count and ANC.
- •Lactating and breast-feeding women.
- •Acute or chronic clinically significant conditions such as uncontrolled congestive heart failure (rule out with MUGA scan, if suspected), liver or kidney dysfunction, uncontrolled hypertension.
- •History of hypersensitivity to drugs with a similar chemical structure to the investigational product or any of its excipients.
- •History of significant drug abuse within 1 year prior to administration of Copper Cu 64 Dotatate. Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine, and crack) within 1 year prior to administration of Copper Cu 64 Dotatate.
- •Participation in other clinical research trials involving evaluation of other investigational treatments within 30 days prior to administration of Copper Cu 64 Dotatate and/or unwilling to allow at least one week before participation in another drug trial following administration of Copper Cu 64 Dotatate.
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available TherapiesEUCTR2009-017671-22-BEEisai Limited500
进行中（未招募）
不适用
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.EUCTR2011-002731-26-ITOVARTIS FARMA700
进行中（未招募）
1 期
Access Program for Asfotase AlfaHypophosphatasiaEUCTR2015-000809-39-FRAlexion Pharma International Sàrl100
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.
No Longer Available
不适用
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsSickle Cell DiseaseNCT03943615Pfizer